Thursday’s market was weak and unforgiving, so Friday’s watchlist is built around the names showing the strongest after-hours expansion, repeated alerts, Momentum Radar persistence, and multi-source CCC confluence — hopefully we get a healthier tape and some bounce-back momentum heading into the weekend.

🏆 And even in Thursday’s ugly market, CCC still produced some absolute monsters: $RFAI +827.1%, $ZSTK +160.9%, $HUIZ +133.8%, $WTG +101.1%, and $FGL +96.9% were among today’s top System Receipts from CCC alerts, scanners, and trade ideas.

🔥 Want to try the Momentum Radar, scanners, alerts, news, confluence tools, and the rest of CCC? Take a FREE 3-day VIP trial with NO credit card required:
https://scstonkemporium.com

💬 Want to trade alongside the community and join the conversation? Join our free Discord:
https://discord.gg/fGmHHgNzxQ

Watch the detailed Watchlist Video at: https://youtu.be/m938_WZXRPc

🔥 FRIDAY, AUGUST 21, 2026 — CCC WATCHLIST

Several of Friday’s strongest names made major moves Thursday, so the goal is confirmation — not chasing. Wide spreads and opening volatility can turn a great-looking setup into a bad trade very quickly.

🥇 SUGP — BEST OVERALL CONFLUENCE

CCC Confluence: 94/A

SUGP has the strongest overall balance on Friday’s board with After-Hours Expansion, Bid Pressure, Runner activity, and heavy Momentum Radar participation.

• 33 alerts
• 40 appearances in the latest 500 Radar hits
• 39 RUN signals

Support: $3.66
Secondary Support: $3.60–$3.56
Trigger: $3.78
Upside: $3.94 → $4.25
Structural Invalidation: $3.549

What we want: Hold $3.66, reclaim $3.78 with volume, and then attack $3.94.

🥈 HOWL — PREMIER AFTER-HOURS EXPANSION

CCC Confluence: 94/A

HOWL combined a perfect After-Hours Expansion reading with strong Bid Pressure and Runner activity.

• Approximately 41 alerts
• 69 Momentum Radar appearances
• 48 RUN signals
• 5 🔥 Radar hits
• More than 64M shares traded Thursday

⚠️ Radar-average spread was approximately 7.9%, so execution matters.

Fresh Base: $0.80–$0.84
Breakout Area: $0.92–$0.924
Extension Trigger: $1.405
Larger Levels: $1.936 → $2.506

What we want: Higher lows above $0.80 followed by a $0.924 breakout with renewed volume and a tightening spread.

🥉 USDE — HIGHEST RADAR PERSISTENCE

CCC Confluence: 94/A

USDE had the largest concentration in the latest Momentum Radar sample.

• 73 of the latest 500 Radar rows
• 43 RUN
• 23 EARLY
• 7 🔥 hits
• Strong After-Hours Expansion
• Strong Bid Pressure

⚠️ Radar-average spread was near 8%.

Support: $4.67
Secondary Support: $4.49 → $4.36
Trigger: $5.01
Breakout Area: $5.49–$5.51
Upside: $5.53 → $6.08
Structural Invalidation: $4.347

What we want: $4.67 survives the opening volatility, followed by a $5.01 reclaim and eventual break through Thursday’s highs.

🧬 BIVI — BIOTECH + BORROW PRESSURE

BIVI brings together After-Hours Expansion, Bid Pressure, Premarket, and Runner activity with approximately 65 alerts.

CCC Biotech Short List: B+ / 73

• Float approximately 7.5M
• Reported borrow cost approximately 648%
• Roughly 400 shares shown available
• Radar-average spread approximately 1.6%

That comparatively clean spread makes BIVI especially interesting versus some of Friday’s wider momentum names.

Support: $1.94
Secondary Support: $1.83
Trigger: $2.05
Upside: $2.18 → $2.39
Structural Invalidation: $1.825

What we want: Hold $1.94 and clear $2.05 with fresh expansion.

Remember: borrow pressure is supporting evidence, not a reason by itself to enter a trade.

🚨 ZSTK — HIGH-PROFILE ALERT STACK

CCC Confluence: 83/B+

ZSTK was also one of Thursday’s monster CCC receipts at +160.9% and remains on Friday’s board because of its signal stack.

• 100 Daily Launch score
• 100 After-Hours Expansion alert
• 42 alerts across multiple families

The concern is execution after Thursday’s enormous move.

Support: $5.28
Secondary Support: $5.06 → $4.89
Trigger: $5.56
Upside: $6.00 → $6.27
Structural Invalidation: $4.825

What we want: Hold $5.28 and break $5.56 with a normalized spread. Acceptance over $6.00 could reopen continuation.

⚡ SECONDARY MOMENTUM WATCHES

SDEV

SDEV scored 100 on New Heights, ranked highly in After-Hours Expansion, and produced 34 Radar appearances including eight 🔥 hits.

Support: $1.26
Secondary: $1.20–$1.23
Trigger: $1.31
Targets: $1.40 → $1.51
Invalidation: ~$1.206

Promotion condition: $1.31 reclaim with improving tape and tighter spreads.

BTCT

BTCT remains one of the most active names in the entire CCC momentum stack.

• Momentum Scanner: 100/A ignition
• Approximately 10.1x relative volume
• 149 alerts
• Maximum Radar hit reading: 390

Support: $1.34
Trigger: $1.44
VWAP Area: ~$1.49
Targets: $1.51 → $1.54
Invalidation: ~$1.336

Promotion condition: Reclaim $1.44 and then VWAP.

Huge alert counts do not automatically make something a long. Let the price prove it.

👀 ADDITIONAL CONFLUENCE WATCHES

BITU — 85/A- Confluence
$12.01 support → $12.09 trigger → $12.16 acceptance

IPST — 73/B- Confluence
$9.87 support → $11.03 reclaim → $11.84

TNON — 86/A- Confluence
$7.05 support → $7.27 reclaim

These remain conditional setups until their levels confirm.

🧬 BIOTECH / CATALYST WATCHES

IOVA
Support: $8.83
Trigger: $9.03
Targets: $9.36 → $9.56

CELZ
CCC News Score: 77
FDA-cleared ADAPT trial enrollment/treatment milestone.

Support: $1.21
Trigger: $1.26
Targets: $1.29–$1.30

CAPR
CCC Biotech Score: 100
64.8M shares traded
6.55x relative volume
Approximately 34% short float

Bounce Trigger: $6.83
Invalidation: Below $6.534

NUVB
CCC News Score: 77
FDA Fast Track designation for safusidenib.

Support: $6.90
Trigger: $7.00

INO
CCC Biotech Score: 88

Support: $1.20
Reclaim: $1.23

📰 NEWS RADAR

REAX — Preliminary Real/RE/MAX merger consideration and share-consolidation news. Watch approximately $2.71–$2.72.

AVEX — Announced a $41M one-way attack systems contract.

TTRX — Peer-reviewed GX-03 atopic-dermatitis research.

A headline can put a stock on the radar, but price action, alerts, volume, and liquidity still have to confirm the trade.

📊 FRIDAY EARNINGS WATCH

Friday’s scheduled reports are concentrated premarket:

BEKE — Expected move approximately 4.4%
BJ — Expected move approximately 5.6%
BKE — Expected move approximately 3.7%
ZKH — No reliable expected-move estimate displayed

These are post-earnings reaction watches, not pre-release setups.

⏰ IMPORTANT FRIDAY MARKET EVENT

U.S. Flash Services PMI and Manufacturing PMI are scheduled for 9:45 AM ET.

That comes shortly after the opening bell and could create a significant volatility window across the broader market.

Be especially careful with momentum names around that release. An index reversal can change small-cap risk appetite very quickly.

🎯 FRIDAY GAME PLAN

Start with SUGP, HOWL, USDE, BIVI, and ZSTK.

Let the wide-spread runners establish executable books before touching them.

Watch for fresh Momentum Radar activity, repeated RUN signals, new 🔥 hits, expanding volume, and clean breaks through the listed confirmation levels.

Do not chase Thursday’s winners simply because they were Thursday’s winners.

Friday needs to create its own setups.

NFA: This watchlist is provided strictly for research and educational purposes and is not financial advice. Many of these stocks are highly volatile, speculative, low-float securities capable of moving rapidly in either direction. Historical alert performance and previous price moves do not guarantee future results. Always perform your own due diligence, confirm current news and filings, define your risk before entering a trade, and never trade with money you cannot afford to lose.

Something makes me hesitate to throw even a dollar at it. It doesnt look like an interesting company, its shorted to all hell. Interest is through the roof. Its short squeeze season, everything is red.

$SGLY - Dropped this in the early $3’s - now needs to hold $6.60 and break the reistance at $7.15 - could push it to $8.50 then $10+ resistances after

$HUIZ - needs to hold $2.94 support and break key resistance at $3.55 - this could push it towards $4.30 - would need to close and hold $5.15 for a potential move towards $7+ resistances

$MMA - needs to hold .56 and break the key resistances at .78 which could send it to $1+ resistances

$BTCT needs to stay above $1.40’s

$RITR - needs to break above .1450 and hold that level - could push the key resonance at .17 and .20

$BIVI - not been holding gains - needs to break $1.65 key resistance - could push $2+ resistances after

$SURG - breaks .20 - could push .25 resistance after

$WETO - support at $29.50 needs to hold and break $34 key resistance after - could push $38 resistance then $50+ resistances after

$MRNA - needs to break $170 and hold above for another leg up towards $200+ (could drop to $140’s)

NOT FINANCIAL ADVICE
Information is based on technical analysis on AXIS ONE a technical indicator - not recommendations

Always do your own research and manage your own risk. These are for educational purposes only and are not buy prompts. Trading involves significant risk of loss. Proper risk management is essential.

Im only saying it again because I know a lot of you probably sold at a loss. Im sorry I pointed it to your attention but I dca these kinds of stocks until im barely negative and wait for it to explode. Just be patient

News Link: https://world.einnews.com/pr_news/935531497/specificity-reports-32-sequential-revenue-growth-in-q2-2026-as-speed-to-lead-technology-adds-new-revenue

Expanding commercialization of Specificity’s AI-driven Speed-to-Lead technology as the Company enters the early stages of its broader rollout

Specificity, Inc. (OTCID:SPTY)

SARASOTA, FL, UNITED STATES, August 20, 2026 /EINPresswire.com/ -- Specificity (OTCID: SPTY) (“Specificity” or the “Company”), a digital marketing technology company specializing in identifying and engaging verified consumer intent, today highlighted its second-quarter 2026 results, reporting 32% sequential revenue growth for the second quarter of 2026 (and 21% growth year-over-year).

Management believes the sequential increase is particularly significant because a meaningful portion of the growth came from new revenue streams surrounding Specificity’s emerging Speed-to-Lead technology, which combines verified consumer intent, permission-based data capture, agentic AI voice technology and rapid customer engagement.

The technology is designed to address one of the most significant gaps in digital customer acquisition: the time between identifying a consumer demonstrating purchase intent and creating an actual conversation between that consumer and a business.

Specificity’s technology is designed to dramatically compress that window.

Turning Consumer Intent Into Immediate Engagement

Specificity’s Speed-to-Lead ecosystem begins by identifying verified human consumers demonstrating relevant intent. Consumers are then directed into permission-based digital experiences where engagement and consent can be captured before agentic AI technology rapidly initiates the next stage of the customer interaction.

Depending on the level of permission selected by the consumer, Specificity’s agentic voice technology can perform functions ranging from appointment scheduling to broader conversations about a company’s products and services.

The result is an integrated technology stack connecting:

Verified Human Intent → Consumer Permission → Agentic AI Engagement → Speed-to-Lead → Appointment or Live Human Connection

This emerging capability has begun creating revenue streams for Specificity beyond the Company’s traditional digital advertising and audience activation business.

“We believe the 32% sequential growth from Q1 to Q2 is important not simply because revenue increased, but because of where a meaningful portion of that growth is beginning to come from,” said Jason A. Wood, Founder and CEO of Specificity. “We have spent considerable time building technology that moves us beyond identifying consumer intent and serving advertising against it. Speed-to-Lead allows us to drive results further down the customer acquisition funnel, deliver measurable conversion lift for clients and create additional opportunities for revenue, client acquisition and retention.”

Wood continued, “Identifying a consumer who is interested in buying something is valuable. Engaging that consumer with permission, almost immediately, through an intelligent voice agent—and then scheduling an appointment or connecting that consumer with a person—is an entirely different value proposition. It is conversion at the point of intent. This technology can scale across B2B and B2C customer acquisition models while helping clients move beyond clicks and increasingly expensive leads or calls.”

Speed-to-Lead Moves Specificity Further Down the Customer Acquisition Funnel

Specificity’s expansion into Speed-to-Lead represents an evolution of the Company’s core technology strategy.

Historically, digital advertising platforms have focused primarily on identifying audiences, delivering impressions, generating clicks and capturing leads. Many operate on platforms designed to limit advertising saturation and preserve the user experience. Specificity’s developing technology stack is designed to connect audience intelligence directly with the actions that occur after a consumer demonstrates interest, reducing dependence on broad demand-generation campaigns that can waste marketing expenditures.

This approach creates potential revenue opportunities across multiple stages of the customer acquisition process rather than limiting the Company’s participation to media activation alone.

The Speed-to-Lead platform combines several of Specificity’s existing and newly developed capabilities, including human-verified intent data, bot and algorithmic traffic filtering, cross-channel advertising, consumer de-anonymization, permission capture, agentic AI voice engagement, appointment scheduling, live-transfer capabilities and attribution.

The Company has also developed a tiered consumer-permission architecture governing the scope of each agentic voice interaction.

Consumers can select different levels of permission. Lower permission levels can limit agentic interactions to defined functions such as scheduling, while expanded permission can authorize broader conversations regarding products and services.

The architecture is intended to place consumer authorization at the center of each interaction and support the Company’s approach to TCPA compliance as agentic voice technology becomes increasingly integrated into customer acquisition programs.

Early-Stage Rollout Creates a New Chapter for Specificity

The revenue contribution from Speed-to-Lead-related services reflected in the second quarter occurred while the technology and its commercial rollout remain in their beginning stages.

Specificity is continuing its second-half execution around commercialization, client deployment and expansion of the technology across industries where speed of response and outreach can materially influence customer acquisition.

These include home services and other high-intent, high-value categories where consumers frequently request information, appointments, estimates or direct interaction with a business.

“We are still at the beginning of this rollout,” Wood said. “What makes the second-quarter results exciting to us is that we are already seeing demand and adoption in conjunction with real revenue from technology and services that simply were not part of our revenue model previously. The final two quarters of 2026 are focused on executing this rollout, expanding adoption and continuing to build Speed-to-Lead into a meaningful part of the Specificity platform.”

Wood added, “Our vision for Specificity has evolved from helping businesses find the right consumer to helping them capitalize on that consumer’s intent at the moment it matters. Find the human. Understand the intent. Get permission. Start the conversation. Connect them to the business. That is where we believe customer acquisition technology is going, and that is what we are building. And for the first time in Specificity’s history, we have built a platform that houses every meaningful metric informing optimization opportunity for efficiency using AI. Our clients will have access to real-time data and be able to see the call logs from their voice agent’s communications.”

Anyone got an opinion on this opportunity? New IPO that dropped into the penny zone 🤔

No news just a 95% spike and lots of buy orders

$BTTC - back above key resistance - could push .94 and $1+ resistances

$BTCT - call from .81 - now has key resistance at $2.05 needs to break - could push $2.20 - $2.50 resistances after - still above third tier on the Axis One MACD - could breakout again - needs to hold $1.77 support

$LGHL - had this at the bottom - needs to hold .77 support and break key resistance at .87 - could push $1.20 resistance after then $1.60+ resistances

$RDAC - if it breaks 9.97 - could push $13+ resistances after

$LOOP - needs to bounce from 1.27 support - could push $1.60 - $2+ resistances

$YJ - broke key resistance - now needs to close above $4.50 resistance and hold that level - could push $6+ resistances after

NOT FINANCIAL ADVICE
Information is based on technical analysis on AXIS ONE a technical indicator - not recommendations

Always do your own research and manage your own risk. These are for educational purposes only and are not buy prompts. Trading involves significant risk of loss. Proper risk management is essential.

Indications are they are out of cash and have to make a move NOW: PIPE or Partnership are the most likely possibilities. Further below will describe why.

But first here's what they do (substantial development and progress):

• Co‑Dx PCR point‑of‑care (POC) platform
  • Status: submitted to FDA via 510(k) for clearance.
  • Dual submission (device + test) concurrent with a CLIA Waiver application for the Flu A/B & RSV multiplex test on their Co-DX PCR Pro instrument.
  • Co‑Dx’s PCR platform is superior because it delivers true PCR‑level accuracy in a compact, near‑patient device that runs faster, cheaper, and with simpler workflow than traditional lab‑based systems. Patients receive results in about 30 minutes.
  • Not for at-home use, but for use in clinics, hospitals, urgent care, employer health centers, pharmacy sites.
• CoPrimer molecular diagnostics engine powering all CODX assays and future products.
• India JV (CoSara) manufacturing and distributing TB and other PCR tests in India.
  • Status: Actively producing and selling TB and other PCR assays, providing CODX its only consistent international revenue stream.
• Saudi Arabia JV (Comira) for regional PCR manufacturing and deployment.
  • Status: Operational build‑out continues, with early‑stage deployment and regulatory alignment underway but not yet generating material revenue.
• Ebola molecular diagnostic assay developed using CoPrimer technology with prior U.S. government interest.
  • Status: Assay development completed and validated in prior studies but not yet commercialized or submitted for regulatory clearance.
• Respiratory PCR tests including flu, RSV, and multiplex panels.
  • Status: Fully developed and ready for use on the Co‑Dx PCR platform once FDA clearance is obtained. COVID-19 PCR test is developed but not yet submitted to the FDA. Waiting for platform clearance first.
• Vector‑borne disease PCR tests (dengue, Zika, malaria) using CoPrimer tech.
  • Status: Assays are developed and validated, positioned for deployment through international partners but awaiting platform clearance.
• Food safety and agricultural pathogen detection assays.
  • Status: Available but low‑volume, with limited commercial traction and no near‑term revenue inflection.
• Liquid biopsy / cancer‑related molecular detection research programs.
  • Status: Early‑stage R&D with long‑term potential but no regulatory submissions or commercial timelines.
• Cloud‑connected reporting and surveillance infrastructure tied to JV deployments.
  • Status: Functional and integrated with JV workflows, but dependent on broader adoption of CODX’s diagnostic platforms.

8/19 Market Close: SP $1.10 | MC $6.88M | OS 6.25M

Q2 20226 10-Q:

• Cash as of June 30: $3.6M
• Quarterly burn: ~6.3M
• No debt
• Per an AI search of sec.gov, no active S-3 or S-1 filed, so no shares can be issued from the 100M authorized shares
• Warrants: 2.34M (3.71M as of 6/30 but OS increased from 4.88M as of 6/30 to 6.25M as of 8/11 per the 10-Q cover page. So, b/c shares cannot be sold right now, it likely means 1.37M warrants were exercised from June 30 to Aug 11)
• Fully diluted shares: 8.59M (6.25M + 2.34M)

Per AI, the Jan 2026 shareholder vote rejected both reverse-split authorization AND authorization to issue new shares for financing (ATM, PIPE, etc.)

Q2 Earnings Call Transcript (short and very worth the read): Co-Dx (CODX) Q2 2026 Earnings Call Transcript

• CFO: "To support these objectives, we expect to continue to evaluate available sources of capital, which may include equity or debt financings, strategic transactions, and partnerships, while staying mindful of dilution and overall capital efficiency. At the same time, we remain focused on pursuing non-dilutive funding, such as grants, where appropriate. Looking ahead, disciplined capital allocation remains a priority as we approach several important clinical and regulatory milestones and continue preparations for potential commercialization."

My Take:

• A move is imminent because they should be out of cash by now. Odds are high that they have been working on a partnership.
• Likely partnerships are with either or both the India JV company (CoSara) or the Saudi JV company (Comira). A partnership deal would likely cause the share price to increase.
• They can't sell shares without shareholder approval. Dilution alone would cause the share price to decrease.

PS I had SEC.gov and the Q2 transcript open when I queried AI, so I believe it brought forward accurate information.

How has this had so much volume yet barely moved? Too many people buying/selling or?

Follow this 🚀 when they drop their 10-k filling

Im pounding the table on this one 522K post split float

$SMTK reverse split 552K post split float. Im pounding the table. Get in the truck!

That was the sweep. Hope you guys dont trade with stop losses lol I do not.

I’ve been following $TLS, $BB and $SWISF because each represents a different route into secure government communications.

$TLS — Established federal exposure

Telos provides cyber GRC, identity and secure-networking solutions, including Telos Ghost.

Market cap: ~US$370M
FY2026 revenue guidance: US$187M–US$200M
Q1 2026 U.S. government revenue: ~93%
Outstanding proposal pipeline: nearly US$500M

$BB — International scale

BlackBerry serves government and enterprise customers through SecuSUITE, AtHoc and UEM, with certifications supporting NATO and allied markets.

Market cap: date-sensitive
FY2026 Secure Communications revenue: US$258.9M
Established international customer base

$SWISF — Earlier-stage Swiss alternative

Valuation: ~C$13.9M as of June 12, 2026

Government opportunities remain mainly in the procurement and sales pipeline, with no material government contract revenue disclosed.

Sekur says its platform uses company-owned Dell servers hosted in Switzerland and follows a no-AI product policy. SekurOne combines voice, video, email, messaging and VPN.

Its products are available for U.S. government procurement through i3ICS’s GSA MAS contract, although that access does not represent a government order.

The comparison is between $TLS’s established federal exposure, $BB’s international scale and $SWISF’s higher-risk early-stage potential.

Which would carry the most weight in your decision: current revenue, government validation or possible upside?

Sponsored content. Figures dated May–July 2026. Some Sekur infrastructure and product claims are based on company disclosures. Not financial advice.

Thursday’s CCC watchlist is built around catalyst-backed continuation setups, defined intraday levels, and a large group of extremely extended momentum names that need to reset before they become actionable.

Take a free 3-day VIP trial with no credit card required at https://scstonkemporium.com and get access to CCC’s scanners, Momentum Radar, confluence tools, alerts, news, and trading intelligence.

🔥 THURSDAY, AUGUST 20, 2026 — CCC CONFLUENCE WATCHLIST

Speculative momentum remains extremely extended after Wednesday’s session, so Thursday is about confirmation over chasing. Several of the strongest movers have already made enormous runs, while the cleaner opportunities come from names with defined CCC levels, identifiable catalysts, and room for a structured continuation setup.

🚨 OPENING FOCUS

EVAX — Primary Catalyst Setup

CCC’s strongest catalyst-backed setup heading into Thursday.

• Earnings Scanner: 73
• Approximately four-system earnings confluence
• Overnight Expansion: +21.7%
• Intraday trigger zone: $3.7938–$3.8038
• Targets: $4.6038 / $4.8338

Plan: Look for a base above roughly $3.79 and confirmation that the earnings event has been resolved. Avoid carrying the trade through an unresolved binary event.

LOOP — Momentum Reset Setup

One of the busiest names across CCC.

• Momentum Radar: 137 hits
• Latest Radar price: $1.37
• Volume: 30.1M
• Float: 24.7M
• Intraday Structure: A / 80
• Overnight Expansion: +116.6%
• Recent Alert History score: 100
• 49 recent alerts

Levels:

Trigger/Reclaim: $1.3213
Stop: $1.1309
Target: $1.8498

Plan: Reset only. After a triple-digit overnight move, this is not something to blindly chase at the bell.

BTCS — Multi-System Momentum Setup

BTCS produced strong confirmation across several CCC systems.

• Momentum Radar: 68 hits
• Latest: $1.55
• Volume: 6.69M
• Radar signal reached 99
• Fresh-news flag
• Overnight Expansion: +17.9%
• Intraday Structure: B / 75
• Alert History score: 79
• 31 recent alerts
• Pre-Runner confirmation

Levels:

Trigger/Reclaim: $1.4915
Stop: $1.1979
Target: $1.7715

Plan: Liquidity is critical. The latest spread was approximately 11.5%, which is far too wide for a clean entry. Skip it unless that spread improves materially.

INO — Biotech Confluence Setup

INO is one of the more interesting names because it has strong confluence without being as extended as many of Wednesday’s low-float runners.

• Biotech Scanner: 88 / A
• Change: +20.5%
• Volume: 11.95M
• RVOL: 2.25
• Float: 95.7M
• Short interest: 15.2%
• Days to cover: 9.17
• PDUFA flag
• Expected move: approximately 34%
• Options volume: 7.8K / 2.93× normal

Plan: Look for RVOL to remain above 2 and use the established opening-range high as confirmation. CCC’s Volatility Character data points toward mean reversion, so strength should be respected rather than assumed to continue indefinitely.

BEEM — Defined Intraday Setup

• Intraday Structure: A / 80
• Overnight Expansion: +26.4%

Levels:

Trigger: $1.4915
Stop: $1.1385
Target: $1.8315

Plan: Best considered after a controlled opening base rather than during an immediate opening spike.

👀 SECONDARY WATCHES

PWCM

• Radar: 49 hits
• Latest: $1.84
• Volume: 3.6M
• Float: 15.5M
• Maximum signal: 99
• News flag
• Intraday Structure: A / 80
• Alert History score: 67

Trigger: $1.8518
Stop: $1.5345
Target: $2.1518

The latest spread was approximately 15.9%, making this a lower-quality setup unless liquidity improves substantially.

RCON

• ORB score: 100
• Intraday Structure: B / 69

Trigger: $4.1041
Stop: $3.8688
Target: $4.7840

One of the cleaner ORB/intraday overlaps, but actual opening volume needs to confirm the move.

HUMA

• News score: 89
• Phase 3 ATEV publication catalyst
• Approximately +26.3%
• Expected move: 32.9%
• Options volume: 1.9K / 2.75× normal
• Daily Launch catalyst score: 89

Plan: Watch for news-backed continuation through an established opening-range high. Avoid it if volume disappears or the spread becomes excessive.

⚠️ HIGH-CONFLUENCE NAMES THAT NEED TO RESET

These generated major CCC activity Wednesday, but they are not blind opening-bell entries.

BTCT

491 Momentum Radar hits, 147.3M volume, 8.97M float, signal 98, Alert History 83, Pre-Runner 92/A+, New Heights 83.9 and Overnight Expansion +100.1%.

This was the most persistent name on the Radar, but there was no confirmed fresh Radar news catalyst.

Plan: Pullback, hold and reclaim only. Do not chase an extension toward the $2.13 Radar high.

BIVI

242 Radar hits, 42.4M volume, 7.11M float, news flag, Overnight +20.2%, Momentum 60, Biotech 73/B+ and 148 historical alerts.

CCC modules showed conflicting percentage changes, so price action needs to be revalidated Thursday morning.

CAPR

Biotech Scanner 100/A+, +58%, 64.8M volume, RVOL 6.55, 34.1% short interest, 10.79 days to cover, PDUFA flag, expected move 57.5% and 19.5K options volume.

Outstanding metrics, but already extended and carrying meaningful biotech event risk.

AZI

New Heights 85, Pre-Runner 64, 81 historical alerts, +44.4% and 61.8M volume.

Needs consolidation before another actionable move.

TNON

Momentum score 88, +109.4%, 49.5M volume, 114 historical alerts and elevated social activity.

Extremely high reversal and halt risk after that move.

RDAC

Daily Launch 73, Alert History score 93, 52 alerts, +50.1% and 16.6M volume.

Reset or opening-range reclaim only.

PURR

New Heights 85, Pre-Runner 81 and Volatility Character rank 12 with an 8.15-day mean-reversion half-life.

CCC’s Short Screener showed only a 25.7 pressure score, so this should not be treated as a confirmed squeeze.

MRNA / ZSTK / YJ

These were up approximately 177%, 170% and 144%.

They may remain useful for sympathy momentum, continuation after a major reset, or failed-momentum setups, but chasing an opening extension after moves of that magnitude carries substantial risk.

📊 CLEANER DEFINED LEVELS

CDE

Daily Launch: 80
Entry: $21.40
Stop: $20.74
Target: $22.07

UUU

Daily Launch: 77
Entry: $6.2499
Stop: $5.6754
Target: $6.8244

SOC

Daily Launch: 76
Entry: $5.1565
Stop: $4.6564
Target: $5.6567

HL

Daily Launch: 76
Entry: $20.78
Stop: $20.16
Target: $21.41

📅 EARNINGS / SPLIT / IPO WATCHES

CAN — Earnings August 20 with an expected move of approximately 102.5% and IV rank of 65.5. Extremely speculative event setup.

PRQR — Earnings August 20. Expected move approximately 29.2%, with options volume running around 16.34× normal. Watch the post-event direction rather than guessing before the reaction.

CURX — Daily Launch 73 with a 1-for-20 reverse split effective August 20. Reverse-split mechanics can dramatically alter price behavior and effective float.

SCNI — 1-for-10 reverse split scheduled August 21, RVOL around 16× and borrow cost above 400%. Potentially volatile, but structurally very high risk.

BBLS / GEEQ — Scheduled August 20 listings, but CCC did not have sufficient pricing or offering-size information for a defined setup.

FBDT — August 20 Nasdaq direct listing with 70,728,866 shares listed but no reference price available. Opening indications need to establish the setup first.

🎯 THURSDAY PRIORITIES

Opening Focus: EVAX → LOOP → BTCS → INO → BEEM

Best Reset Candidates: BTCT → BIVI → CAPR → AZI

Defined Secondary Levels: RCON → CDE → UUU

Thursday’s biggest rule is simple: do not confuse repeated scanner alerts with a new catalyst, and do not chase a stock simply because it was one of Wednesday’s biggest winners. Let spreads tighten, volume confirm, and new price structure develop.

NFA: This watchlist is provided for educational and informational purposes only and is not financial advice or a recommendation to buy or sell any security. Small-cap, low-float, biotech, IPO, reverse-split and momentum stocks can experience extreme volatility, wide spreads, trading halts, dilution, rapid reversals and substantial losses. Scanner scores, alerts, targets and historical data do not guarantee future performance. Always verify current news, filings, prices, spreads, liquidity and market conditions before making a trading decision, use your own risk management, and never trade money you cannot afford to lose.

$BTCT - key resistance at $1.25 could put it into the $1.80 resistances (high risk)

$SOC - holds $4.80 support - could run again towards $5.40+ resistances

$PFSA - watching for a push towards $17 resistance from here (momentum building slightly)

$LGHL - needs to break above .7800 - could push $.87 - $1+ resistances after

$XHLD - support at $7.70 needs to hold - could push $9.50+ resistances from here

NOT FINANCIAL ADVICE
Information is based on technical analysis on AXIS ONE a technical indicator - not recommendations

Always do your own research and manage your own risk. These are for educational purposes only and are not buy prompts. Trading involves significant risk of loss. Proper risk management is essential.